Wedson F Araújo1, Marcelo A Naves2, Juliana N Ravanini3, Nestor Schor2, Vicente P C Teixeira4. 1. Department of Pathology, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, Brazil. Electronic address: wedson.araujo@yahoo.com.br. 2. Department of Medicine, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, Brazil. 3. Department of Pathology, Universidade de São Paulo (USP), São Paulo, Brazil. 4. Department of Pathology, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, Brazil; Department of Medicine, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, Brazil.
Abstract
OBJECTIVES: Renal cell carcinoma (RCC) is the most frequent type of cancer among renal neoplasms in adults and responds poorly to radiotherapy and chemotherapy. There is evidence that blockade of the renin-angiotensin system (RAS) might have antineoplastic effects. The aim of this study was to investigate the effects of RAS blockade on RCC in a murine model. METHODS AND MATERIALS: Murine renal cancer cells (Renca) were injected (1 × 10(5)) into the subcapsular space of the left kidney of BALB/c mice (8 wk of age). The animals were divided into 4 groups: a control group (no treatment), angiotensin-receptor blockers group (losartan 100mg/kg/d), angiotensin-converting enzyme inhibitor group (captopril 10mg/kg/d), and angiotensin-receptor blockers +angiotensin-converting enzyme inhibitor group (losartan 100mg/kg/d +captopril 10mg/kg/d). The animals received the drugs by gavage for 21 days after inoculation, beginning 2 days before tumor induction, and were then euthanized. After killing the animals, the kidneys and lungs were removed, weighed, and processed for histopathological and immunohistochemical analyses. Angiogenesis and vascular microvessels were assessed with the antibodies anti-vascular endothelial growth factor and anti-CD34. RESULTS: Angiotensin II-inoculated animals developed renal tumors. Treated animals presented smaller tumors, regardless of the therapeutic regimen, and far fewer lung metastases in both quantity and dimension compared with the controls. The expression of vascular endothelial growth factor and CD34 were significantly decreased in renal tumors of treated animals compared with the controls. CONCLUSIONS: Our findings suggest that blockade of RAS decreases tumor proliferation and metastatic capacity of RCC in this experimental model.
OBJECTIVES:Renal cell carcinoma (RCC) is the most frequent type of cancer among renal neoplasms in adults and responds poorly to radiotherapy and chemotherapy. There is evidence that blockade of the renin-angiotensin system (RAS) might have antineoplastic effects. The aim of this study was to investigate the effects of RAS blockade on RCC in a murine model. METHODS AND MATERIALS: Murinerenal cancer cells (Renca) were injected (1 × 10(5)) into the subcapsular space of the left kidney of BALB/c mice (8 wk of age). The animals were divided into 4 groups: a control group (no treatment), angiotensin-receptor blockers group (losartan 100mg/kg/d), angiotensin-converting enzyme inhibitor group (captopril 10mg/kg/d), and angiotensin-receptor blockers +angiotensin-converting enzyme inhibitor group (losartan 100mg/kg/d +captopril 10mg/kg/d). The animals received the drugs by gavage for 21 days after inoculation, beginning 2 days before tumor induction, and were then euthanized. After killing the animals, the kidneys and lungs were removed, weighed, and processed for histopathological and immunohistochemical analyses. Angiogenesis and vascular microvessels were assessed with the antibodies anti-vascular endothelial growth factor and anti-CD34. RESULTS: Angiotensin II-inoculated animals developed renal tumors. Treated animals presented smaller tumors, regardless of the therapeutic regimen, and far fewer lung metastases in both quantity and dimension compared with the controls. The expression of vascular endothelial growth factor and CD34 were significantly decreased in renal tumors of treated animals compared with the controls. CONCLUSIONS: Our findings suggest that blockade of RAS decreases tumor proliferation and metastatic capacity of RCC in this experimental model.
Authors: Peio Errarte; Maider Beitia; Itxaro Perez; Lorea Manterola; Charles H Lawrie; Jon Danel Solano-Iturri; Julio Calvete-Candenas; Miguel Unda; José I López; Gorka Larrinaga Journal: PLoS One Date: 2017-08-15 Impact factor: 3.240
Authors: Sam Siljee; Bridget Milne; Helen D Brasch; Nicholas Bockett; Josie Patel; Paul F Davis; Andrew Kennedy-Smith; Tinte Itinteang; Swee T Tan Journal: Biomolecules Date: 2021-04-07
Authors: José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244